- Adaptimmune Announces Changes to Board and Executive Leadership Team
Nov 17, 2025 · newsfilecorp.com
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes to the Company's Board of Directors ("Board") and its Executive Leadership team, which are effective from November 14, 2025. Christopher (Chris) Hill, currently Chief Financial Officer ("CFO") of the Company, has been appointed as Chief Executive Officer ("CEO") and a Director of the Company, succeeding Adrian Rawcliffe who has left in connection with the Company's restructuring.
- ADAPTIMMUNE ANNOUNCES CHANGES TO BOARD AND EXECUTIVE LEADERSHIP TEAM
Nov 17, 2025
PHILADELPHIA, PENNSYLVANIA AND OXFORD, UNITED KINGDOM--(NEWSFILE CORP. - NOVEMBER 17, 2025) - ADAPTIMMUNE THERAPEUTICS PLC (OTC PINK: ADAPY) ("ADAPTIMMUNE" OR THE "COMPANY") TODAY ANNOUNCED CHANGES TO THE COMPANY'S BOARD OF DIRECTORS ("BOARD") AND ITS EXECUTIVE LEADERSHIP TEAM, WHICH ARE EFFECTIVE FROM NOVEMBER 14, 2025. CHRISTOPHER (CHRIS) HILL, CURRENTLY CHIEF FINANCIAL OFFICER ("CFO") OF THE COMPANY, HAS BEEN APPOINTED AS CHIEF EXECUTIVE OFFICER ("CEO") AND A DIRECTOR OF THE COMPANY, SUCCEEDING ADRIAN RAWCLIFFE WHO HAS LEFT IN CONNECTION WITH THE COMPANY'S RESTRUCTURING.
- AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
Oct 21, 2025 · businesswire.com
WASHINGTON--(BUSINESS WIRE)--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP.
- AHF: 80 ORGANIZATIONS DENOUNCE GILEAD ON PRICE HIKES GUTTING ADAP
Oct 21, 2025
WASHINGTON--(BUSINESS WIRE)--AHF: 80 ORGANIZATIONS DENOUNCE GILEAD ON PRICE HIKES GUTTING ADAP.
- Adaptimmune Announces Delisting from Nasdaq
Oct 20, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's Board of Directors (the "Board") has determined to initiate the delisting of its American Depositary Shares ("ADSs"), each representing six ordinary shares, from The Nasdaq Capital Market ("Nasdaq") and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "As we noted previously, the transaction with USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC (collectively, "US WorldMeds") followed an extensive review of strategic alternatives and represented the best path forward for Adaptimmune, our patients and other stakeholders. Since closing the transaction on July 31, 2025, we have been restructuring to support the assets transferred to US WorldMeds, and have continued our efforts to maximize value from our remaining assets including programs targeting PRAME and CD70. The delisting from Nasdaq and deregistration should facilitate cost reductions and further support our goal to maximize value going forward."
As previously reported by the Company, the Company received a written notice on September 22, 2025, from the Nasdaq Hearings Panel (the "Panel") confirming that the Company had been granted an exception period to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the "Bid Price Rule"). The Company had until December 1, 2025 to regain compliance with the Bid Price Rule. Failure to regain compliance by December 1, 2025 would result in the delisting of the Company's ADSs from Nasdaq.
On October 16, 2025, the Company notified The Nasdaq Stock Market, LLC, pursuant to authorization by the Board on October 15, 2025, that it intends to file a Form 25 with the U.S. Securities and Exchange Commission (the "SEC") on or about October 28, 2025 to effect the voluntary delisting of the Company's ADSs from Nasdaq and to deregister the ADSs under Section 12(b) of the Exchange Act. Following confirmation by The Nasdaq Stock Market, LLC on October 17, 2025, the Company currently expects that the trading of its ADSs on Nasdaq will be suspended following the closing of trading on Nasdaq on or about October 27, 2025.
Following the delisting, any trading in the Company's ADSs would only occur in privately negotiated sales and potentially on an over-the-counter market. The Company currently expects that its ADSs will be quoted on the OTC Pink Limited Market, a market operated by OTC Markets Group Inc. (an "OTC market"), so that a trading market may continue to exist for its ADSs. There is no guarantee, however, that a broker will continue to make a market in the ADSs and that trading of the ADSs will continue on an OTC market or otherwise.
Story Continues
Ninety days after the date of filing of the Form 25, the deregistration of the Company's ADSs under Section 12(b) of the Exchange Act is expected to become effective. Following the delisting of the Company's ADSs from Nasdaq, the Company intends to file a Form 15 with the SEC certifying that it has fewer than 300 shareholders of record, upon which the Company's filing obligations under the Exchange Act will immediately be suspended, including the obligations to file all periodic reports.
The Board believes that the decision to delist the ADSs from Nasdaq and deregister and suspend the Company's reporting obligations under the Exchange Act is in the best interests of the Company and the holders of its ordinary shares and ADSs. As the Company continues with its efforts to maximize value from its remaining assets, the Board has determined that the burdens associated with operating as a registered public company listed on Nasdaq outweigh any advantages to the Company and the holders of its ordinary shares and ADSs. The Board's decision was based on careful review of numerous factors, including the potential for eliminating the significant costs associated with preparing and filing periodic reports with the SEC and the legal, audit and other expenses associated with being a public reporting company listed on Nasdaq, as well as the substantial costs and demands on management's time under the Sarbanes-Oxley Act of 2002, SEC rules and Nasdaq listing standards.
About Adaptimmune
We are a biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. In August 2024, the U.S. Food and Drug Administration ("FDA") approved our first biologics license application ("BLA") for TECELRA® (afamitresgene autoleucel) ("TECELRA"), which is the first engineered T-cell therapy for the treatment of a solid tumor cancer approved in the U.S. In July 2025, TECELRA was acquired by US WorldMeds alongside letetresgene autoleucel ("lete-cel"), for people with synovial sarcoma and myxoid liposarcoma, in relation to which a commercial launch was planned for 2026. A third clinical candidate, uza-cel, and the collaboration with Galapagos related to that cell therapy was also assigned to US Worldmeds as part of the transaction. We are working to ensure a smooth transition of TECELRA, lete-cel and uza-cel to US WorldMeds. We have also developed certain pre-clinical assets including our PRAME directed T-cell therapy and our CD-70 directed TRuC therapy. We are looking for strategic options in relation to these assets.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Exchange Act. Forward-looking statements address our expected future business, financial performance, financial condition, as well as the results of operations and often contain words such as "anticipate" "believe," "expect," "may," "plan," "potential," "will," and similar expressions. Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on these forward-looking statements because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: risks associated with, and the timing and effectiveness of, the Company's voluntary delisting from Nasdaq; the Company's plans with respect to the delisting and deregistration of its ADSs; uncertainties regarding eligibility for and timing of quotation on an OTC market; and the trading of the Company's ADSs following the voluntary delisting of the ADSs from Nasdaq. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations and Media Relations
Adrian Rawcliffe, Chief Executive Officer
Adrian.Rawcliffe@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271003
View Comments
- Adaptimmune Announces Delisting from Nasdaq
Oct 20, 2025 · newsfilecorp.com
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's Board of Directors (the "Board") has determined to initiate the delisting of its American Depositary Shares ("ADSs"), each representing six ordinary shares, from The Nasdaq Capital Market ("Nasdaq") and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "As we noted previously, the transaction with USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC (collectively, "US WorldMeds") followed an extensive review of strategic alternatives and represented the best path forward for Adaptimmune, our patients and other stakeholders.
- ADAPTIMMUNE ANNOUNCES DELISTING FROM NASDAQ
Oct 20, 2025
PHILADELPHIA, PENNSYLVANIA AND OXFORD, UNITED KINGDOM--(NEWSFILE CORP. - OCTOBER 20, 2025) - ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ: ADAP) ("ADAPTIMMUNE" OR THE "COMPANY") TODAY ANNOUNCED THAT THE COMPANY'S BOARD OF DIRECTORS (THE "BOARD") HAS DETERMINED TO INITIATE THE DELISTING OF ITS AMERICAN DEPOSITARY SHARES ("ADSS"), EACH REPRESENTING SIX ORDINARY SHARES, FROM THE NASDAQ CAPITAL MARKET ("NASDAQ") AND DEREGISTRATION UNDER SECTION 12(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE "EXCHANGE ACT"). ADRIAN RAWCLIFFE, ADAPTIMMUNE'S CHIEF EXECUTIVE OFFICER: "AS WE NOTED PREVIOUSLY, THE TRANSACTION WITH USWM CT, LLC, A SUBSIDIARY OF US WORLDMEDS PARTNERS, LLC (COLLECTIVELY, "US WORLDMEDS") FOLLOWED AN EXTENSIVE REVIEW OF STRATEGIC ALTERNATIVES AND REPRESENTED THE BEST PATH FORWARD FOR ADAPTIMMUNE, OUR PATIENTS AND OTHER STAKEHOLDERS.
- After-Hours Trading Sees Sharp Gains Across Emerging Growth Names
Sep 19, 2025
(RTTNews) - Several small-cap names extended their momentum into after-hours trading on Thursday, posting sharp gains following active regular sessions. Recent strategic updates, leadership moves, and pipeline developments appear to be driving renewed attention across these stocks, with key milestones still ahead.
Adaptimmune Therapeutics plc (ADAP) surged in after-hours trading, jumping 30% to $0.2020 from its regular session close of $0.16. This dramatic overnight move follows a nearly 98% gain during Thursday's trading session, where the stock closed at $0.16 after opening at just $0.08. ADAP's volume also spiked, with over 705 million shares traded, well above its average daily volume of 60 million.
The rally appears to be driven by renewed investor interest, although no company-specific news was released on September 19. For the second quarter ended June 30, 2025, Adaptimmune reported a net loss of $30.3 million, or a loss of $0.02 per ordinary share. Total revenue for the quarter was $13.7 million, driven primarily by product sales of TECELRA, which generated $11.1 million from 16 patients invoiced, representing over 150% growth compared to the first quarter.
In a major strategic development, the company, in August, announced the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million upfront with up to $30 million in future milestone payments. Following the transaction, Adaptimmune has repaid its debt and is restructuring to maximize value from remaining assets, including PRAME and CD70 directed T-cell therapies.
**
Butterfly Network Inc. (BFLY) extended its rally into after-hours trading, climbing 10.58% to $2.09 following a strong regular session performance where the stock closed at $1.89, up 15.95% from the previous close. The surge comes amid heightened investor interest and volume, with over 12 million shares traded, triple its average daily volume.
The momentum appears to be fueled by recent recognition and strategic developments. On September 18, Butterfly Network was named to TIME's list of the World's Top HealthTech Companies for 2025, highlighting its innovation in AI-powered ultrasound imaging. Earlier this month, the company appointed Victor Ku as Chief Technology Officer, signaling a renewed focus on advancing its technology stack. Additionally, a recent study published in JAMA confirmed that Butterfly-enabled point-of-care ultrasound (POCUS) programs significantly reduce hospital stay and costs, further validating its clinical impact.
**
Aquestive Therapeutics Inc. (AQST) continued its upward momentum in after-hours trading, rising 7.69% to $5.32 following a solid regular session gain of 2.28%, where it closed at $4.94. The stock has been steadily climbing, now up nearly 39% year-to-date, and trading near the upper end of its 52-week range of $2.12 to $5.80.
While no fresh headlines were released on September 19, recent developments have kept investor sentiment bullish. Earlier this month, the FDA confirmed it will not require an advisory committee meeting to review Aquestive's NDA for Anaphylm, its sublingual epinephrine film for treating severe allergic reactions. This decision streamlines the regulatory path and significantly derisks the approval process, with a PDUFA date set for January 2026. Additionally, Aquestive recently secured a $75 million strategic funding agreement to support the potential launch of Anaphylm, further reinforcing its commercial readiness.
**
ALX Oncology Holdings Inc. (ALXO) extended its gains in after-hours trading, rising 9.17% to $1.19 following a 3.81% increase during Thursday's regular session, where it closed at $1.09. The latest catalyst appears to be insider buying activity.
On September 17, CEO Jason Lettmann purchased 92,233 shares of ALXO, bringing his total holdings to over 305,000 shares. This move signals confidence from leadership and has caught the attention of investors tracking insider trends. While no new clinical data were released this week, the company's lead candidate, Evorpacept, remains in multiple Phase 1 and Phase 2 trials across gastric, urothelial, head and neck, and breast cancers, in collaboration with major partners like Jazz Pharmaceuticals, MD Anderson Cancer Center, and Sanofi.
**
Ekso Bionics Holdings Inc. (EKSO) continued its upward momentum in after-hours trading, rising 5.37% to $4.51 after closing Thursday's regular session at $4.28, a gain of 9.74%. This marks a notable move for the company, which is currently trading near the midpoint of its 52-week range of $2.73 to $19.05.
There were no new announcements on September 19, but recent developments may be contributing to the stock's strength. Ekso's inclusion in the NVIDIA Connect Program earlier this year has helped spotlight its efforts to integrate AI into its wearable exoskeleton technologies. The company also launched Virtual eksoUniversity, a platform designed to support continuing education for physical therapists and assistants, which could help broaden adoption of its rehabilitation devices.
**
CEL-SCI Corp. (CVM) rose 5.27% in after-hours trading on Thursday, reaching $9.39 after closing the regular session at $8.92, up 1.02% for the day. While there were no new announcements on September 19, recent developments continue to shape the company's outlook.
CEL-SCI recently completed a $10 million public offering to support its ongoing clinical and regulatory efforts. Last month, the company filed for Breakthrough Medicine Designation in Saudi Arabia for its lead candidate, Multikine, aimed at treating head and neck cancer. If granted, the designation could allow for patient access and reimbursement within approximately 60 days. Additionally, CEO Geert Kersten increased his stake by 66.91% through a purchase of 29,197 shares at an average price of $6.85.
** </p>
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- Discover the most active stocks in Tuesday's session.
Sep 16, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.
[mostactive]
TODAY'S MOST ACTIVE STOCKS
TICKER
CHANGE
COMMENT
ADAP [https://www.chartmill.com/stock/quote/ADAP/profile]
22.97%
424.43M shares of ADAPTIMMUNE THERAPEUTICS-ADR (NASDAQ:ADAP [https://www.chartmill.com/stock/quote/ADAP/profile]) have been traded so far today. The share price increased by 22.97% today, indicating positive momentum in the market.
CODX [https://www.chartmill.com/stock/quote/CODX/profile]
63.44%
Investors have been actively buying and selling shares of CO-DIAGNOSTICS INC (NASDAQ:CODX [https://www.chartmill.com/stock/quote/CODX/profile]) in today's session, resulting in a trading volume of 196.87M shares. CODX is advancing 63.44% today, demonstrating strong growth and market performance.
OPEN [https://www.chartmill.com/stock/quote/OPEN/profile]
-4.37%
So far 187.56M shares of OPENDOOR TECHNOLOGIES INC (NASDAQ:OPEN [https://www.chartmill.com/stock/quote/OPEN/profile]) have traded in today's session. Investors witnessed a notable decrease in share prices, with a loss of 4.37%.
BBAI [https://www.chartmill.com/stock/quote/BBAI/profile]
15.7%
162.73M shares of BIGBEAR.AI HOLDINGS INC (NYSE:BBAI [https://www.chartmill.com/stock/quote/BBAI/profile]) have been traded so far today. Investors witnessed a substantial increase in share prices, with a gain of 15.7%.
WOLF [https://www.chartmill.com/stock/quote/WOLF/profile]
-15.69%
The trading session for WOLFSPEED INC (NYSE:WOLF [https://www.chartmill.com/stock/quote/WOLF/profile]) has seen a substantial volume of 126.99M shares traded so far today. With a decline of 15.69%, WOLF is facing a downward movement in its share price today.
BITF [https://www.chartmill.com/stock/quote/BITF/profile]
13.31%
The trading session for BITFARMS LTD/CANADA (NASDAQ:BITF [https://www.chartmill.com/stock/quote/BITF/profile]) has seen a substantial volume of 113.95M shares traded so far today. Leading to a price increase of 13.31%.
APVO [https://www.chartmill.com/stock/quote/APVO/profile]
7.64%
The trading session for APTEVO THERAPEUTICS INC (NASDAQ:APVO [https://www.chartmill.com/stock/quote/APVO/profile]) has seen a substantial volume of 107.98M shares traded so far today. The share price increased by 7.64% today, indicating positive momentum in the market. Earlier today the company had a press release: Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML [https://www.chartmill.com/news/APVO/accwirecq-2025-9-16-mipletamig-delivers-100-remission-rate-in-cohort-3-of-rainier-trial-for-aml].
SNAP [https://www.chartmill.com/stock/quote/SNAP/profile]
1.68%
The trading volume for SNAP INC - A (NYSE:SNAP [https://www.chartmill.com/stock/quote/SNAP/profile]) has been quite high, with 85.28M shares exchanged. Shares are rising by 1.68%. A press release (Snap Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 20, 2025 to Discuss Your Rights - SNAP [https://www.chartmill.com/news/SNAP/newmediawire-2025-9-16-snap-inc-sued-for-securities-law-violations-contact-levi-and-korsinsky-before-october-20-2025-to-discuss-your-rights-snap]) was released earlier today.
NVDA [https://www.chartmill.com/stock/quote/NVDA/profile]
-1.56%
The trading volume for NVIDIA CORP (NASDAQ:NVDA [https://www.chartmill.com/stock/quote/NVDA/profile]) has reached 82.57M shares in today's session, reflecting significant market participation. Shares are falling by 1.56%. Earlier today the company had a press release: CrowdStrike Teams with NVIDIA to Build, Power, and Secure the Agentic Ecosystem [https://www.chartmill.com/news/NVDA/bizwire-2025-9-16-crowdstrike-teams-with-nvidia-to-build-power-and-secure-the-agentic-ecosystem].
NIO [https://www.chartmill.com/stock/quote/NIO/profile]
6.93%
The trading session for NIO INC - ADR (NYSE:NIO [https://www.chartmill.com/stock/quote/NIO/profile]) has seen a substantial volume of 80.86M shares traded so far today. Investors witnessed a substantial increase in share prices, with a gain of 6.93%.
For the full most active stocks list go to our most active stocks [https://www.chartmill.com/stock/market/most-active-and-unusual-volume/usa-nyse-nasdaq-amex] screener.
- Let's take a look at the stocks that are in motion in today's session.
Sep 16, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
[topmovers]
TOP GAINERS
TICKER
CHANGE
COMMENT
FGI [https://www.chartmill.com/stock/quote/FGI/profile]
138.0%
In an impressive move, FGI INDUSTRIES LTD'S (NASDAQ:FGI [https://www.chartmill.com/stock/quote/FGI/profile]) shares recorded a 138.0% increase, closing at $9.46 during Tuesday's session.
CODX [https://www.chartmill.com/stock/quote/CODX/profile]
67.03%
CO-DIAGNOSTICS INC (NASDAQ:CODX [https://www.chartmill.com/stock/quote/CODX/profile]) witnessed a notable 67.03% uptick in its shares, reaching $0.59 during Tuesday's session. The stock is trading 20.12% higher than a month ago.
BGI [https://www.chartmill.com/stock/quote/BGI/profile]
56.47%
Investors celebrated as BIRKS GROUP INC (NYSEARCA:BGI [https://www.chartmill.com/stock/quote/BGI/profile]) experienced a 56.47% rise in its shares, closing at $1.33 during Tuesday's session. In the last month the share price increased with 23.07%.
CNFR [https://www.chartmill.com/stock/quote/CNFR/profile]
39.83%
Exciting news for CONIFER HOLDINGS INC (NASDAQ:CNFR [https://www.chartmill.com/stock/quote/CNFR/profile]) as its stock price surged 39.83% to $1.58 during Tuesday's session. In the last month the stock gained 46.39%.
WBTN [https://www.chartmill.com/stock/quote/WBTN/profile]
39.37%
Exciting news for WEBTOON ENTERTAINMENT INC (NASDAQ:WBTN [https://www.chartmill.com/stock/quote/WBTN/profile]) as its stock price surged 39.37% to $20.85 during Tuesday's session. A press release (Disney and WEBTOON Entertainment Broaden Relationship to Create New Digital Comics Platform [https://www.chartmill.com/news/WBTN/bizwire-2025-9-15-disney-and-webtoon-entertainment-broaden-relationship-to-create-new-digital-comics-platform]) was released yesterday.
ILLR [https://www.chartmill.com/stock/quote/ILLR/profile]
31.73%
TRILLER GROUP INC (NASDAQ:ILLR [https://www.chartmill.com/stock/quote/ILLR/profile]) experienced a significant 31.73% increase, reaching $1.12 during Tuesday's session. The stock is trading 88.6% higher than a month ago.
ADAP [https://www.chartmill.com/stock/quote/ADAP/profile]
28.98%
ADAPTIMMUNE THERAPEUTICS-ADR'S (NASDAQ:ADAP [https://www.chartmill.com/stock/quote/ADAP/profile]) stock price increased by 28.98% to $0.09. In the last 3 months the stock lost 73.68%.
DMAAR [https://www.chartmill.com/stock/quote/DMAAR/profile]
27.53%
DRUGS MADE IN AMERICA AC-RTS'S (NASDAQ:DMAAR [https://www.chartmill.com/stock/quote/DMAAR/profile]) shares rose 27.53% to $0.22.
SONN [https://www.chartmill.com/stock/quote/SONN/profile]
26.53%
SONNET BIOTHERAPEUTICS HOLDI'S (NASDAQ:SONN [https://www.chartmill.com/stock/quote/SONN/profile]) shares rose 26.53% to $7.01. Shareholders saw the stock price going 56.5% higher in the past month.
AEI [https://www.chartmill.com/stock/quote/AEI/profile]
26.17%
ALSET INC (NASDAQ:AEI [https://www.chartmill.com/stock/quote/AEI/profile]) rose 26.17% to $4.05 during Tuesday's after hours session. The stock is trading 172.0% higher than a month ago.
For the full top gainers list go to our top gainers [https://www.chartmill.com/stock/market/top-gainers-and-losers/usa-nyse-nasdaq-amex] page.
TOP LOSERS
TICKER
CHANGE
COMMENT
BNGO [https://www.chartmill.com/stock/quote/BNGO/profile]
-40.97%
BIONANO GENOMICS INC (NASDAQ:BNGO [https://www.chartmill.com/stock/quote/BNGO/profile]) encountered a 40.97% decrease in its shares, reaching $1.64 during Tuesday's session. In the last year the share price dropped with 88.61%.
CJET [https://www.chartmill.com/stock/quote/CJET/profile]
-28.3%
CHIJET MOTOR CO INC'S (NASDAQ:CJET [https://www.chartmill.com/stock/quote/CJET/profile]) shares fell 28.3% to $0.08. In the last month the share price dropped with 92.26%.
LPSN [https://www.chartmill.com/stock/quote/LPSN/profile]
-27.33%
LIVEPERSON INC'S (NASDAQ:LPSN [https://www.chartmill.com/stock/quote/LPSN/profile]) stock price is declining with 27.33% to a price of $0.64.
FAAS [https://www.chartmill.com/stock/quote/FAAS/profile]
-25.46%
DIGIASIA CORP'S (NASDAQ:FAAS [https://www.chartmill.com/stock/quote/FAAS/profile]) stock price encountered a 25.46% decline, reaching $0.09 during Tuesday's session. In the last month the share price dropped with 54.25%.
NAOV [https://www.chartmill.com/stock/quote/NAOV/profile]
-23.08%
NANOVIBRONIX INC (NASDAQ:NAOV [https://www.chartmill.com/stock/quote/NAOV/profile]) encountered a 23.08% decrease in its shares, reaching $8.23 during Tuesday's session. Shareholders saw the stock price going 82.59% higher in the past month.
ORIS [https://www.chartmill.com/stock/quote/ORIS/profile]
-23.0%
There was a notable decline in ORIENTAL RISE HOLDINGS LTD'S (NASDAQ:ORIS [https://www.chartmill.com/stock/quote/ORIS/profile]) shares, as they dropped 23.0% to $0.14 during Tuesday's session. Shareholders saw the stock price going 50.99% higher in the past month.
VIVS [https://www.chartmill.com/stock/quote/VIVS/profile]
-22.59%
There was a notable decline in VIVOSIM LABS INC'S (NASDAQ:VIVS [https://www.chartmill.com/stock/quote/VIVS/profile]) shares, as they dropped 22.59% to $3.7 during Tuesday's session. In the last month the stock gained 170.0%.
BIAF [https://www.chartmill.com/stock/quote/BIAF/profile]
-22.03%
Investors witnessed a 22.03% decrease in BIOAFFINITY TECHNOLOGIES INC'S (NASDAQ:BIAF [https://www.chartmill.com/stock/quote/BIAF/profile]) stock price, which closed at $0.27 during Tuesday's session. In the last month the stock gained 50.32%.
RCT [https://www.chartmill.com/stock/quote/RCT/profile]
-21.99%
The market experienced a downward movement in REDCLOUD HOLDINGS PLC'S (NASDAQ:RCT [https://www.chartmill.com/stock/quote/RCT/profile]) stock price, closing at $0.87 with a 21.99% decrease during Tuesday's session. In the last month the stock lost 49.09%.
NBY [https://www.chartmill.com/stock/quote/NBY/profile]
-21.64%
During Tuesday's session, NOVABAY PHARMACEUTICALS INC'S (NYSEARCA:NBY [https://www.chartmill.com/stock/quote/NBY/profile]) shares took a tumble, falling 21.64% to $2.15. Shareholders saw the stock price going 344.0% higher in the past month.
Our top losers [https://www.chartmill.com/stock/market/top-gainers-and-losers/usa-nyse-nasdaq-amex] page will show you the full list.
